Suman Dasgupta

Suman Dasgupta


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2018 in Biochimie
Verified
Journal Article
Closed access
DBDipanjan Banerjee
Dipanjan Banerjee
ASArchana Sinha
Archana Sinha
SSSudeshna Saikia
Sudeshna Saikia
BGBhaskarjyoti Gogoi
Bhaskarjyoti Gogoi
ARArvind K. Rathore
Arvind K. Rathore
SDSuman Dasgupta
Suman Dasgupta


5 December 2022 in Diabetes
Verified
Journal Article
Closed access
PDF file
DPDebarun Patra
Debarun Patra
SRSoumyajit Roy
Soumyajit Roy
LALeena Arora
Leena Arora
SKShaheen Wasil Kabeer
Shaheen Wasil Kabeer
SSSatpal Singh
Satpal Singh
DPDurba Pal
Durba Pal
Under the condition of chronic obesity, an increased level of free fatty acids along with low oxygen tension in the adipose tissue creates a pathophysiological adipose tissue microenvironment (ATenv), leading to the impairment of adipocyte function and insulin resistance. Here, we found the synergistic effect of hypoxia and lipid (H + L) surge in fostering adipose tissue macrophage (ATM) inflammation and polarization. ATenv significantly increased miR-210-3p expression in ATMs which promotes NF-κB activation–dependent proinflammatory cytokine expression along with the downregulation of anti-inflammatory cytokine expression. Interestingly, delivery of miR-210-3p mimic significantly increased macrophage inflammation in the absence of H + L co-stimulation, while miR-210-3p inhibitor notably compromised H + L–induced macrophage inflammation through increased production of suppressor of cytokine signaling 1 (SOCS1), a negative regulator of the NF-κB inflammatory signaling pathway. Mechanistically, miR-210 directly binds to the 3′-UTR of SOCS1 mRNA and silences its expression, thus preventing proteasomal degradation of NF-κB p65. Direct delivery of anti–miR-210-3p LNA in the ATenv markedly rescued mice from obesity-induced adipose tissue inflammation and insulin resistance. Thus, miR-210-3p inhibition in ATMs could serve as a novel therapeutic strategy for managing obesity-induced type 2 diabetes.

22 March 2024 in Molecular Oncology
Verified
Journal Article
Open access
LALeena Arora
Leena Arora
DPDebarun Patra
Debarun Patra
SRSoumyajit Roy
Soumyajit Roy
Sidhanta NandaSidhanta Nanda
Sidhanta Nanda
NSNavneet Singh
Navneet Singh
DPDurba Pal
Durba Pal
In most cancers, tumor hypoxia downregulates the expression of C‐C motif chemokine 2 (CCL2), and this downregulation has been implicated in monocyte infiltration and tumor progression; however, the molecular mechanism is not yet clear. We compared noncancerous and lung‐adenocarcinoma human samples for hypoxia‐inducible factor 1‐alpha (HIF‐1A), microRNA‐210‐3p (mir‐210‐3p), and CCL2 levels. Mechanistic studies were performed on lung adenocarcinoma cell lines and 3D tumor spheroids to understand the role of hypoxia‐induced miR‐210‐3p in the regulation of CCL2 expression and macrophage polarization. HIF‐1Α stabilization increases miR‐210‐3p levels in lung adenocarcinoma and impairs monocyte infiltration by inhibiting CCL2 expression. Mechanistically, miR‐210‐3p directly binds to the 3′untranslated region (UTR) of CCL2 mRNA and silences it. Suppressing miR‐210‐3p substantially downregulates the effect of hypoxia on CCL2 expression. Monocyte migration is significantly hampered in miR‐210‐3p mimic‐transfected HIF‐1A silenced cancer cells. In contrast, inhibition of miR‐210‐3p in HIF‐1A‐overexpressed cells markedly restored monocyte migration, highlighting a direct link between the miR‐210‐3p level and tumor monocyte burden. Moreover, miR‐210‐3p inhibition in 3D tumor spheroids promotes monocyte recruitment and skewing towards an antitumor M1 phenotype. Anti‐hsa‐miR‐210‐3p‐locked nucleic acid (LNA) delivery in a lung tumor xenograft zebrafish model caused tumor regression, suggesting that miR‐210‐3p could be a promising target for immunomodulatory therapeutic strategies against lung adenocarcinoma.

1 September 2014 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
BGBhaskarjyoti Gogoi
Bhaskarjyoti Gogoi
PCPriyajit Chatterjee
Priyajit Chatterjee
SMSandip Mukherjee
Sandip Mukherjee
ABAlak Kumar Buragohain
Alak Kumar Buragohain
SBSamir Bhattacharya
Samir Bhattacharya
SDSuman Dasgupta
Suman Dasgupta

30 August 2019 in Biochemical Journal
Verified
Journal Article
Closed access
PDF file
SCSaynaz A. Choudhary
Saynaz A. Choudhary
NBNikita Bora
Nikita Bora
DBDipanjan Banerjee
Dipanjan Banerjee
LALeena Arora
Leena Arora
Anindhya Sundar DasAnindhya Sundar Das
Anindhya Sundar Das
SDSuman Dasgupta
Suman Dasgupta
Saturated free fatty acid-induced adipocyte inflammation plays a pivotal role in implementing insulin resistance and type 2 diabetes. Recent reports suggest A2A adenosine receptor (A2AAR) could be an attractive choice to counteract adipocyte inflammation and insulin resistance. Thus, an effective A2AAR agonist devoid of any toxicity is highly appealing. Here, we report that indirubin-3′-monoxime (I3M), a derivative of the bisindole alkaloid indirubin, efficiently binds and activates A2AAR which leads to the attenuation of lipid-induced adipocyte inflammation and insulin resistance. Using a combination of in silico virtual screening of potential anti-diabetic candidates and in vitro study on insulin-resistant model of 3T3-L1 adipocytes, we determined I3M through A2AAR activation markedly prevents lipid-induced impairment of the insulin signaling pathway in adipocytes without any toxic effects. While I3M restrains lipid-induced adipocyte inflammation by inhibiting NF-κB dependent pro-inflammatory cytokines expression, it also augments cAMP-mediated CREB activation and anti-inflammatory state in adipocytes. However, these attributes were compromised when cells were pretreated with the A2AAR antagonist, SCH 58261 or siRNA mediated knockdown of A2AAR. I3M, therefore, could be a valuable option to intervene adipocyte inflammation and thus showing promise for the management of insulin resistance and type 2 diabetes.